Checkpoint inhibitors for basal cell carcinoma – pro
Research on the use of PD-1 and PDL-1 inhibitors is just beginning. There are case reports and one ongoing trial (Chang et al). There are no published resutls of trials or guideline recommendations.
Anne Lynn S. Chang, Duy C Tran, Richard Brotherton, Sunil Reddy, A. Dimitrios Colevas, Pembrolizumab with or without vismodegib in treating metastatic or unresectable basal cell skin cancer. ournal of Clinical Oncology 35, no. 15_suppl -
Falchook GS, Leidner R, Stankevich E, et al. Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810. Journal for Immunotherapy of Cancer. 2016;4:70.
Evan J. LipsonEmail author, Mohammed T. Lilo, Aleksandra Ogurtsova, Jessica Esandrio, Haiying Xu, Patricia Brothers, Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade. Journal for ImmunoTherapy of Cancer20175:23